Physician profile
Robert A Marini
NPI 1184656373
$1,083.49
in general payments reported to CMS, 2019-2025
12 companies · $80.67 in 2025
The $80.67 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $87.86 · 2021: $187 · 2022: $56.59 · 2023: $96.62 · 2024: $53.33 · 2025: $80.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.67 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $206.81 | 2019-2025 | Xtampza |
| Si-Bone, INC. | $148.72 | 2021 | |
| Horizon Therapeutics Plc | $133.68 | 2019-2021 | |
| Daiichi Sankyo INC. | $127.94 | 2019 | |
| Pfizer INC. | $53.74 | 2019 | |
| Vertical Pharmaceuticals, LLC | $47.37 | 2019 | |
| Scilex Pharmaceuticals INC. | $23.64 | 2019 | |
| Forte Bio-Pharma LLC | $14.26 | 2024 | Prolate, Nalocet |
| Kowa Pharmaceuticals America, INC. | $13.36 | 2023 | Seglentis |
| Redhill Biopharma INC. | $12.49 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Marini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.